Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Descartes-11 in Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Descartes-11
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-06-21

Last Posted Date: 2024-10-01

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 25

Registration Number: NCT03994705

Locations: 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
Medical College of Wisconsin, Madison, Wisconsin, United States

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor, Adult

Interventions: Other: TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Other: Radiotherapy

First Posted Date: 2019-06-20

Last Posted Date: 2021-03-18

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 6

Registration Number: NCT03992326

Locations: 🇨🇭
CHUV Oncology Department, Lausanne, Vaud, Switzerland

Optimizing PTCy Dose and Timing

Phase 1

Recruiting

Conditions: Hematologic Neoplasms
Graft Versus Host Disease

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2019-06-12

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 400

Registration Number: NCT03983850

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Phase 2

Recruiting

Conditions: Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

Interventions: Drug: Thiotepa
Drug: Treosulfan
Drug: Fludarabine Phosphate
Biological: Rabbit Anti-Thymocyte Globulin
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection

First Posted Date: 2019-06-10

Last Posted Date: 2024-07-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT03980769

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Phase 2

Recruiting

Conditions: Acute Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Radiation: Total-Body Irradiation
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Peripheral Blood Stem Cell
Drug: Tacrolimus
Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Drug: Methotrexate
Drug: Cyclosporine
Drug: Busulfan
Drug: Sirolimus
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Biospecimen Collection

First Posted Date: 2019-05-31

Last Posted Date: 2024-08-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT03970096

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Phase 2

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Letetresgene autoleucel (lete-cel, GSK3377794)
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-05-30

Last Posted Date: 2024-10-11

Lead Sponsor: Adaptimmune

Target Recruit Count: 103

Registration Number: NCT03967223

Locations: 🇪🇸
Hospital Virgen Del Rocio, Sevilla, Spain
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States

and more 34 locations

Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Transplant-Related Hematologic Malignancy

Interventions: Drug: Fludarabine
Drug: ARA-C
Drug: Treosulfan
Procedure: Peripheral Blood Stem Cell Transplant

First Posted Date: 2019-05-23

Last Posted Date: 2023-11-18

Lead Sponsor: Ciceri Fabio

Target Recruit Count: 15

Registration Number: NCT03961919

Locations: 🇮🇹
Ospedale San Raffaele, Milano, Lombardia, Italy

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Phase 1

Completed

Conditions: Myeloma, Plasma-Cell
Myeloma-Multiple

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rimiducid
Biological: Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells

First Posted Date: 2019-05-22

Last Posted Date: 2021-09-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT03958656

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Early Phase 1

Conditions: Multiple Myeloma

Interventions: Biological: Anti-BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Immune inhibitors

First Posted Date: 2019-05-09

Last Posted Date: 2021-08-31

Lead Sponsor: Hrain Biotechnology Co., Ltd.

Target Recruit Count: 10

Registration Number: NCT03943472

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Phase 1

Active, not recruiting

Conditions: Relapsed/Refractory Large B Cell Lymphoma
Relapsed/Refractory Follicular Lymphoma

Interventions: Genetic: ALLO-501
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-05-06

Last Posted Date: 2023-12-01

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 74

Registration Number: NCT03939026

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
St. Davids South Austin Medical Center, Austin, Texas, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy